Recombinant Rabbit OX40 / TNFRSF4 / CD134 Protein, Fc Tag, 100 µg

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Source
Recombinant Rabbit OX40, Fc Tag (OX0-R5254) is expressed from human 293 cells (HEK293). It contains AA Ala 19 - Gln 208 (Accession # O02764).
Predicted N-terminus: Ala 19

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 47.3 kDa. As a result of different glycosylation, the protein migrates as 48 kDa and 68 kDa under reducing (R) condition, and 120-135 kDa under non-reducing (NR) condition (SDS-PAGE).

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>85% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Nonylphenol exacerbates ovalbumin-induced allergic rhinitis via the TSLP-TSLPR/IL-7R pathway and JAK1/2-STAT3 signaling in a mouse model"
Wang, Cao, Zhao et al
Ecotoxicol Environ Saf (2022) 243, 114005
(2) "Road testing new CAR design strategies in multiple myeloma"
Rana, Murphy, Kort et al
Front Immunol (2022) 13, 957157
(3) "Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects"
Cortellino, Raveane, Chiodoni et al
Cell Rep (2022) 40 (8), 111256
Showing 1-3 of 1847 papers.